自体免疫的共同研究·授权契约(2016年～2025年)

本报告提供了 2016 年至 2025 年间全球生物製药行业的详细数据，包括 943 项自体免疫合作和许可协议的条款和条件。

目录

摘要整理

第1章 简介

第2章 自体免疫契约趋势

• 简介
• 过去数年的自体免疫契约
• 自体免疫契约:各类型契约
• 自体免疫契约:各产品部门
• 自体免疫契约:各开发阶段
• 自体免疫契约:各技术类型

第3章 自体免疫契约相关财务的契约条件

• 简介
• 自体免疫契约相关公开的财务条件
• 自体免疫契约的标题金额
• 自体免疫契约的预付款
• 自体免疫契约的阶段性付款
• 自体免疫契约的特许权率

第4章 主要自体免疫的谈判者与契约

• 简介
• 在自体免疫契约中最活跃
• 自体免疫领域的最活跃的谈判者清单
• 前几名的自体免疫契约(金额)

第5章 自体免疫契约文件名录

• 简介
• 有合同檔的自体免疫的合作伙伴契约

第6章 自体免疫契约:治疗标的

• 简介
• 契约:各自体免疫治疗标的
• 契约名录
• 契约名录 - 自体免疫契约:各企业(A～Z)(2016年～2025年)
• 契约名录 - 自体免疫契约:各技术类型(2016年～2025年)
• 契约类型定义
• 关于Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Current Partnering的近几年报告标题

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 943 autoimmune deals from 2016 to 2025.

The report includes coverage of the following autoimmune diseases:

• Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
• The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.
• Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
• Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.
• The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
• In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse autoimmune collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.

Autoimmune Collaboration and Licensing Deals includes:

• Trends in autoimmune dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of autoimmune deal records covering pharmaceutical and biotechnology
• The leading autoimmune deals by value
• Most active autoimmune licensing dealmakers

In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

• 2.1. Introduction
• 2.2. Autoimmune deals over the years
• 2.3. Autoimmune deals by deal type
• 2.4. Autoimmune deals by industry sector
• 2.5. Autoimmune deals by stage of development
• 2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

• 3.1. Introduction
• 3.2. Disclosed financials terms for autoimmune deals
• 3.3. Autoimmune deal headline values
• 3.4. Autoimmune deal upfront payments
• 3.5. Autoimmune deal milestone payments
• 3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

• 4.1. Introduction
• 4.2. Most active in autoimmune dealmaking
• 4.3. List of most active dealmakers in autoimmune
• 4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

• 5.1. Introduction
• 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by autoimmune therapeutic target
• Deal Directory
• Deal Directory - Autoimmune deals by company A-Z 2016 to 2025
• Deal Directory - Autoimmune deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Autoimmune deals since 2016
• Figure 2: Autoimmune deals by deal type since 2016
• Figure 3: Autoimmune deals by industry sector since 2016
• Figure 4: Autoimmune deals by stage of development since 2016
• Figure 5: Autoimmune deals by technology type since 2016
• Figure 6: Autoimmune deals with a headline value
• Figure 7: Autoimmune deals with upfront payment values
• Figure 8: Autoimmune deals with milestone payment
• Figure 9: Autoimmune deals with royalty rates
• Figure 10: Active autoimmune dealmaking activity since 2016
• Figure 11: Top autoimmune deals by value since 2016